BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN - News) announced today that it has initiated a phase Ib clinical trial of SGN-40 in combination with Revlimid® (lenalidomide) and dexamethasone, a steroid, for patients with relapsed or refractory multiple myeloma. As a result, the company will receive a $4 million milestone payment from its collaborator Genentech, Inc.
